HAUPTMENÜ
AWARDS
Wund(er)heilung mit Amnion – DGFG erhält deutschen Wundpreis 2021
Ausschreibung DGNI-Pflege- und Therapiepreis 2022
Ausschreibung: Otsuka Team Award Psychiatry+ 2021
BGW-Gesundheitspreis 2022: Gute Praxis aus der Altenpflege gesucht!
Aktionsbündnis Patientensicherheit vergibt Deutschen Preis für Patientensicherheit 2021 an herausragende…
VERANSTALTUNGEN
20.-22.01.2022 online: ANIM: NeuroIntensivmediziner diskutieren neue Erkenntnisse zu COVID-19
8.-10. September 2021: Weimar Sepsis Update 2021 – Beyond the…
13.09. – 18.09.2021: Viszeralmedizin 2021
24.06. – 26.06.2021: 27. Jahrestagung der Deutschen Gesellschaft für Radioonkologie
17.06. – 19.06.2021: 47. Jahrestagung der Gesellschaft für Neonatologie und…
DOC-CHECK LOGIN
European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer
Positive benefit-risk balance confirmed as second and third line treatment
London, United Kingdom (October 21, 2011) – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has clarified its opinion on pioglitazone-containing anti-diabetes medicines and the risk of bladder cancer. The Committee confirmed its previous opinion, introducing some clarifications for transparency and consistency purposes: pioglitazone remains a valid treatment option for certain patients with type 2 diabetes, when certain other treatments (metformin) have not been suitable or have failed to work adequately.
The new warnings and contraindications recommended in July 2011 remain in place.
The CHMP reviewed its July 2011 opinion on pioglitazone on the request of the Commission as it failed to gain endorsement in the Standing Committee on Medicinal Products for Human Use. This body, which consists of representatives of all EU Member States, has to be consulted before the European Commission transforms the Agency’s opinion into legally enforceable decisions.
In July 2011 the CHMP had finalised a review of pioglitazone and the risk of bladder cancer. The Committee found that there was a small increased risk of bladder cancer. However, because the Committee considered that there are a limited number of patients who cannot be adequately treated by other treatments, the Committee concluded that pioglitazone should remain available as a treatment option, but that prescribers should carefully select patients and monitor their response to treatment. With these clarifications, the CHMP is reminding doctors that pioglitazone remains a valid treatment option for certain patients with type 2 diabetes, when certain other treatments (metformin) have not been suitable or have failed to work adequately.
The updated opinion has now been sent to the European Commission and is expected to be endorsed by the Standing Committee within the next two to three months.
European Medicines Agency, 21.10.2011 (tB).